Tech Company Financing Transactions
Qu Biologics Funding Round
Qu Biologics, operating out of Burnaby BC, secured $2.5 million from private investors.
Transaction Overview
Company Name
Announced On
12/31/2015
Transaction Type
Venture Equity
Amount
$2,500,000
Round
Undisclosed
Investors
Proceeds Purpose
This latest round allows Qu to expand its clinical footprint by initiating a randomized, controlled clinical trial in one or more cancer indications in 2016.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4475 Wayburne Dr. 305
Burnaby BC, V5G 4X4
Canada
Burnaby BC, V5G 4X4
Canada
Phone
Website
Email Address
Not Recorded
Overview
Qu Biologics is developing a platform of new immunotherapeutic treatments. Our Site Specific Immunomodulators (SSIs) aim to activate the body's immune system to reverse the chronic inflammation underlying many conditions including cancer and immune-related diseases, such as Crohn's disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Hal Gunn
Chief Medical Officer
Simon Sutcliffe
VP - Finance
Nicole Clendinning
VP - Manufacturing
Alun Rees
VP - Operations
James Pankovich
VP - Operations
Gillian Vandermeirsch
Browse more venture capital transactions:
Prev: 12/31/2015: 915 Labs venture capital transaction
Next: 12/31/2015: Ender Labs venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs